Atherosclerosis—the buildup of fatty plaques in arteries—is the primary driver of heart disease, the world’s leading cause of death. Traditional treatments focus heavily on lowering LDL cholesterol with statins, but emerging research suggests inflammation within the artery wall may play an even more critical role in plaque progression.
Enter Tauroursodeoxycholic acid (TUDCA), a bile acid derivative long used for liver conditions and now gaining attention as a supplement. Recent preclinical studies indicate TUDCA may slow atherosclerosis without altering blood cholesterol levels, instead targeting inflammatory pathways directly.
The Key Study: TUDCA Reduces Plaques in Mice
A 2024 study published in iScience investigated TUDCA’s effects in mice fed a high-fat diet to induce atherosclerosis.
- Mice supplemented with TUDCA showed significantly reduced atherosclerotic plaques in their arteries, as visualized by oil red O staining (which highlights lipid deposits in red).
- Importantly, TUDCA did not lower total cholesterol or LDL levels—ruling out the conventional lipid-lowering mechanism.
- Histological analysis confirmed decreased lipid accumulation in arterial walls.
The researchers pinpointed the mechanism: TUDCA alleviates endoplasmic reticulum (ER) stress in macrophages (immune cells in the artery wall). This reduces activation of the AIM2 inflammasome, a pro-inflammatory complex. As a result:
- Macrophages exhibit improved cholesterol efflux capacity (their ability to remove excess cholesterol).
- Fewer macrophages turn into “foam cells”—the hallmark of atherosclerotic plaques that drive inflammation and plaque growth.
In essence, TUDCA interrupts a vicious cycle: high-fat diets trigger ER stress and inflammation, leading to foam cell formation and more plaque. TUDCA breaks this cycle by calming inflammation at its source.
Why This Matters Beyond Cholesterol
This anti-inflammatory approach could complement or even alternative traditional therapies. Statins lower cholesterol but don’t fully address arterial inflammation in all patients. TUDCA’s effects appear independent of lipids, potentially offering benefits for those with normal cholesterol but high inflammation (e.g., metabolic syndrome).
Supporting evidence includes:
- TUDCA’s known role in reducing ER stress across tissues.
- Related studies showing bile acids influence vascular health, with some (like certain conjugated forms) linked to lower atherosclerosis risk.
Human Relevance: Dosing, Safety, and Caveats
While the evidence is promising in animal models, human trials specifically for atherosclerosis are lacking. TUDCA has been studied in humans for other conditions (e.g., liver disease, ALS, insulin resistance), showing:
- Common dosing: 250–1,500 mg/day, often split into 2–3 doses. Some protocols use 500–1,000 mg/day for metabolic benefits; higher (1,750–2,000 mg) for specific trials.
- Safety: Generally well-tolerated. Mild gastrointestinal side effects (diarrhea, abdominal pain) are most common, affecting ~10–20% of users, especially at higher doses. Rare skin reactions reported. No serious hepatotoxicity.
- Extrapolated from mouse studies: Effective doses translate to roughly 1,500–2,000 mg/day in humans, but this is not validated for cardiovascular outcomes.
Important disclaimer: TUDCA is a supplement, not an approved drug for heart disease. Always consult a healthcare provider before starting, especially if on medications or with existing conditions. It may interact with bile acid pathways or affect gut microbiome.
The Bottom Line
Preclinical data suggest TUDCA could represent a novel, inflammation-targeted strategy against atherosclerosis—one that works orthogonally to cholesterol-lowering drugs. This aligns with growing recognition that plaque stability and inflammation matter as much as (or more than) lipid levels alone.
More human research is needed to confirm these benefits. In the meantime, TUDCA’s favorable safety profile makes it an intriguing option for those exploring metabolic health supplements.
Stay curious—science on bile acids and heart disease is evolving rapidly. What do you think: ready to discuss TUDCA with your doctor?